PMID- 15293139
OWN - NLM
STAT- MEDLINE
DCOM- 20041102
LR  - 20041117
IS  - 0944-1174 (Print)
IS  - 0944-1174 (Linking)
VI  - 39
IP  - 7
DP  - 2004 Jul
TI  - Types of human leukocyte antigen and decrease in HCV core antigen in serum for 
      predicting efficacy of interferon-Alpha in patients with chronic hepatitis C: 
      analysis by a prospective study.
PG  - 674-80
AB  - BACKGROUND: A prospective study was conducted to evaluate the influence of host 
      factors, including human leukocyte antigen (HLA), and viral factors, including 
      hepatitis C virus (HCV) core antigen, on the response to interferon (IFN)-Alpha. 
      METHODS: Natural IFN-Alpha was given to 66 patients with chronic hepatitis C at a 
      dose of 9 million units per day for 2 weeks, followed by 9 million units three 
      times a week for 22 weeks. RESULTS: Sustained virological response without 
      detectable HCV RNA in serum 24 weeks after the end of IFN therapy was achieved in 
      21 patients, while it was not in 32 patients; the remaining 13 patients were not 
      evaluated. HCV core antigen and HCV RNA started to decrease 1 and 4 weeks, 
      respectively, after the commencement of IFN in responders ( P = 0.02 and P = 
      0.05, respectively). On univariate analysis, age of 50 years or less ( P < 
      0.001); lack of HLA DR6 ( P = 0.018) or DR52 ( P < 0.041); platelets more than 14 
      x 10(4)/mm(3) ( P = 0.031); HCV core antigen 500 fmol/l or less ( P = 0.001); and 
      HCV RNA 100 KIU/ml or less were predictive of response. On multivariate analysis, 
      age 50 years or less (odds ratio [OR], 4.009; P = 0.039); lack of HLA DR6 (OR, 
      8.130; P = 0.027); IFN-naive (OR, 11.63; P = 0.016); HCV core antigen 500 fmol/l 
      or less (OR, 10.61; P = 0.007); and genotypes other than 1b (OR, 8.929; P = 
      0.010) were predictive of response. CONCLUSIONS: Lack of HLA DR6 determined the 
      response to IFN. HCV core antigen was useful in predicting and monitoring the 
      response to IFN.
FAU - Muto, Hidetomo
AU  - Muto H
AD  - Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 
      390-8621, Japan.
FAU - Tanaka, Eiji
AU  - Tanaka E
FAU - Matsumoto, Akihiro
AU  - Matsumoto A
FAU - Yoshizawa, Kaname
AU  - Yoshizawa K
FAU - Kiyosawa, Kendo
AU  - Kiyosawa K
CN  - Nagano Interferon Treatment Research Group
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Gastroenterol
JT  - Journal of gastroenterology
JID - 9430794
RN  - 0 (Antiviral Agents)
RN  - 0 (HLA Antigens)
RN  - 0 (Hepatitis C Antigens)
RN  - 0 (Interferon-alpha)
RN  - 0 (Viral Core Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antiviral Agents/*therapeutic use
MH  - Female
MH  - HLA Antigens/*analysis
MH  - Hepatitis C Antigens/*blood
MH  - Hepatitis C, Chronic/*drug therapy/immunology/virology
MH  - Humans
MH  - Interferon-alpha/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Viral Core Proteins/*immunology
EDAT- 2004/08/05 05:00
MHDA- 2004/11/04 09:00
CRDT- 2004/08/05 05:00
PHST- 2003/05/21 00:00 [received]
PHST- 2003/11/21 00:00 [accepted]
PHST- 2004/08/05 05:00 [pubmed]
PHST- 2004/11/04 09:00 [medline]
PHST- 2004/08/05 05:00 [entrez]
AID - 10.1007/s00535-003-1364-8 [doi]
PST - ppublish
SO  - J Gastroenterol. 2004 Jul;39(7):674-80. doi: 10.1007/s00535-003-1364-8.